Table 1. The different topical and systemic JAK inhibitors with the different doses, dosing frequencies and current phase in clinical trials.
| Active ingredient | Designation | Trade name | Target molecule | Application | Formulation | Dose | Frequency | Study phase | References |
|---|---|---|---|---|---|---|---|---|---|
| Delgocitinib | JTE-052 | Corectim® | JAK1, JAK2, JAK3, TYK2 | topical | Ointment | 0,5% | 2 × daily | Approved | [23, 24, 26, 27] |
| Ruxolitinib | JAK1, JAK2 | topical | Cream | 0,15%, 0,5%, 1,5% | 1 – 2 × daily | Phase III | [29, 30, 32] | ||
| Tofacitinib | JAK1, JAK3 | topical | Ointment | 2% | 2 × daily | Phase IIa | [36] | ||
| Cerdulatinib | DMVT-502/RVT-502 | JAK, SYK | topical | Gel | 0,37% | 2 × daily | Phase Ib | [38] | |
| SNA-125 | JAK3, TrkA | topical | Planned | ||||||
| Tofacitinib | CP-690,550 | Xeljanz® | JAK1, JAK3 | oral | Tablet | 5 mg | 2 × daily | Proof-of-concept | [58] |
| Gusacitinib | ASN-002 | JAK1 | oral | Tablet | 20 mg, 40 mg, 80 mg | 1 × daily | Phase Ib | [61] | |
| Abrocitinib | PF -04965842 | JAK1 | oral | Tablet | 100 mg, 200 mg | 1 × daily | Phase III | [52, 55, 56, 57] | |
| Upadacitinib | ABT-494 | Rinvoq® | JAK1 | oral | Tablet | 7.5 mg, 15 mg, 30 mg | 1 × daily | Phase III | [47, 48] |
| Baricitinib | Olumiant® | JAK1, JAK2 | oral | Tablet | 4 mg (2 mg) | 1 × daily | approved | [41, 42, 43] |
JAK = Janus kinase; SYK = Spleen tyrosine kinase; TrkA = Tropomyosin receptor kinase A.